IGF1R and prostate cancer: According to target prediction and pathway enrichment, the bioactive compound stadium oxygen can act on the signal pathways of prostate cancer, pathways in cancer, proteoglycans in cancer, and focal adhesion and controls the progress of liver cancer by inhibiting the overexpression of IGF1R.